| 08/13/2026 9:55 AM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 08/06/2026 10:55 AM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 08/02/2026 11:15 PM | NeuroSense Therapeutics (1875091) Filer | Form EFFECT | |
| 07/31/2026 3:15 PM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 07/31/2026 3:16 PM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 07/30/2026 3:05 PM | NeuroSense Therapeutics (1875091) Filer | Form F-3/A | |
| 07/22/2026 7:37 AM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 06/29/2026 8:30 AM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 06/25/2026 8:25 AM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 06/17/2026 3:30 PM | Eisenberg Or (1721412) Reporting NeuroSense Therapeutics (1875091) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/17/2026 3:30 PM | Ben-Noon Alon (1901198) Reporting NeuroSense Therapeutics (1875091) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
Get the Latest News and Ratings for NRSNW and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for NeuroSense Therapeutics and its competitors with MarketBeat's FREE daily newsletter.
|
| 06/11/2026 8:00 AM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 06/09/2026 9:13 AM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 06/08/2026 8:05 AM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 04/28/2026 2:38 PM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 04/24/2026 8:20 AM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 04/06/2026 8:20 AM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 04/03/2026 8:27 AM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 04/01/2026 3:25 PM | Eisenberg Or (1721412) Reporting NeuroSense Therapeutics (1875091) Issuer | Form 3 Initial statement of beneficial ownership of securities | |
| 04/01/2026 3:26 PM | Eisenberg Or (1721412) Reporting NeuroSense Therapeutics (1875091) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 03/31/2026 3:16 PM | Mandil-Levin Revital (2125058) Reporting NeuroSense Therapeutics (1875091) Issuer | Form 3 Initial statement of beneficial ownership of securities | |
| 03/31/2026 8:29 AM | NeuroSense Therapeutics (1875091) Filer | Form 20-F Registration statement / Annual report / Transition report | |
| 03/31/2026 8:29 AM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 03/30/2026 7:49 AM | Binder Hagit (2118272) Reporting NeuroSense Therapeutics (1875091) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 03/30/2026 7:51 AM | Ben-Noon Alon (1901198) Reporting NeuroSense Therapeutics (1875091) Issuer | Form 3 Initial statement of beneficial ownership of securities | |
| 03/24/2026 9:11 AM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 03/18/2026 2:35 PM | Binder Hagit (2118272) Reporting NeuroSense Therapeutics (1875091) Issuer | Form 3 Initial statement of beneficial ownership of securities | |
| 03/18/2026 2:35 PM | Leuchtenberger Mark (1303315) Reporting NeuroSense Therapeutics (1875091) Issuer | Form 3 Initial statement of beneficial ownership of securities | |
| 03/18/2026 2:35 PM | Golan Roy (1999257) Reporting NeuroSense Therapeutics (1875091) Issuer | Form 3 Initial statement of beneficial ownership of securities | |
| 03/18/2026 2:36 PM | Claiborne Cary J (1370930) Reporting NeuroSense Therapeutics (1875091) Issuer | Form 3 Initial statement of beneficial ownership of securities | |
| 03/18/2026 2:36 PM | NeuroSense Therapeutics (1875091) Issuer Tracik Ferenc (2120172) Reporting | Form 3 Initial statement of beneficial ownership of securities | |
| 03/16/2026 11:27 AM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 03/11/2026 7:00 AM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 02/18/2026 8:21 AM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 02/09/2026 8:30 AM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 01/29/2026 4:28 PM | NeuroSense Therapeutics (1875091) Filer | Form F-3 Registration statement for securities of certain foreign private issuers | |
| 01/06/2026 4:27 PM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 12/22/2025 10:49 AM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 12/08/2025 7:00 AM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 12/04/2025 7:39 AM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 11/26/2025 3:15 PM | NeuroSense Therapeutics (1875091) Filer | Form 424B3 | |
Why Boston Ships In Natural Gas It Already Has at Home (Ad) A tanker called the Iberica Knutsen once sailed 2,272 miles from Trinidad and Tobago to deliver liquefied natural gas to Boston.
The odd part: the Marcellus Shale, one of the largest natural gas reserves in the world, sits just a few hundred miles away.
Porter Stansberry spent years digging into why this happens and what it means for the American energy system. Uncover the full story behind Boston's costly LNG imports |
| 11/25/2025 11:15 PM | NeuroSense Therapeutics (1875091) Filer | Form EFFECT | |
| 11/21/2025 5:36 AM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 10/28/2025 3:26 PM | NeuroSense Therapeutics (1875091) Filer | Form F-3 Registration statement for securities of certain foreign private issuers | |
| 10/06/2025 8:06 AM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 09/25/2025 8:23 AM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 09/10/2025 1:35 PM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 09/04/2025 7:59 AM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 09/04/2025 8:01 AM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |